SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Meditech (MTCH) Viraplex - possible cancer treatment
MTCH 48.25-0.6%Sep 30 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Elliot who wrote (35)6/7/1999 1:24:00 PM
From: OLD JAKE JUSTUS  Read Replies (1) of 39
 
The below was posted on another thread. It must have caught the eyes of some folks. This is just my guess:

>>>
Stock under 3cents that will run on Mon.
stonecold [205.188.199.184]

--------------------------------------------------------------------------------
MTCH was #9 on the OTC bb most active list on volume of almost 8 mill.
MTCH has been developing Viraplex(R) for over 12 years, including testing done by
the NCI(National Cancer Institute). Viraplex is for the treatment of certain types of
cancer, including breast, prostate, and lung.
MTCH is planning to introduce an over-the-counter topical version of its compound
MTCH-24 for the treatment of Herpes Simplex I(cold sores).
Management has had talks with a telemarketing group to telemarket the product to
thousands of independent drug and convenience stores.
They have also had talks with an internet group to handle sales direct to the customer.
MTCH plans to sell its product through retail chain drug stores and various mass
merchandisers.<<<
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext